As of 2025-11-18, the EV/EBITDA ratio of Fusion Antibodies PLC (FAB.L) is -8.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FAB.L's latest enterprise value is 14.14 mil GBP. FAB.L's TTM EBITDA according to its financial statements is -1.67 mil GBP. Dividing these 2 quantities gives us the above FAB.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 19.5x | 16.5x |
| Forward P/E multiples | 9.9x - 18.0x | 13.5x |
| Fair Price | (16.65) - (25.18) | (20.96) |
| Upside | -235.9% - -305.5% | -271.1% |
| Date | EV/EBITDA |
| 2025-11-14 | -8.68 |
| 2025-11-13 | -8.64 |
| 2025-11-12 | -8.47 |
| 2025-11-11 | -9.18 |
| 2025-11-10 | -8.48 |
| 2025-11-07 | -9.03 |
| 2025-11-06 | -8.99 |
| 2025-11-05 | -9.17 |
| 2025-11-04 | -8.83 |
| 2025-11-03 | -9.37 |
| 2025-10-31 | -9.39 |
| 2025-10-30 | -9.34 |
| 2025-10-29 | -8.82 |
| 2025-10-28 | -9.18 |
| 2025-10-27 | -9.54 |
| 2025-10-24 | -9.56 |
| 2025-10-23 | -9.70 |
| 2025-10-22 | -10.06 |
| 2025-10-21 | -10.06 |
| 2025-10-20 | -10.07 |
| 2025-10-17 | -10.45 |
| 2025-10-16 | -10.05 |
| 2025-10-15 | -9.17 |
| 2025-10-14 | -9.36 |
| 2025-10-13 | -9.54 |
| 2025-10-10 | -9.39 |
| 2025-10-09 | -9.52 |
| 2025-10-08 | -10.41 |
| 2025-10-07 | -10.59 |
| 2025-10-06 | -10.78 |
| 2025-10-03 | -10.98 |
| 2025-10-02 | -11.82 |
| 2025-10-01 | -11.65 |
| 2025-09-30 | -12.18 |
| 2025-09-29 | -12.90 |
| 2025-09-26 | -12.74 |
| 2025-09-25 | -12.52 |
| 2025-09-24 | -12.88 |
| 2025-09-23 | -13.07 |
| 2025-09-22 | -12.19 |
| 2025-09-19 | -11.68 |
| 2025-09-18 | -11.29 |
| 2025-09-17 | -12.18 |
| 2025-09-16 | -9.71 |
| 2025-09-15 | -10.60 |
| 2025-09-12 | -10.80 |
| 2025-09-11 | -11.11 |
| 2025-09-10 | -11.12 |
| 2025-09-09 | -10.95 |
| 2025-09-08 | -10.07 |